Navigation Links
Cepheid Signs Group Purchasing Contract With Premier Healthcare Alliance, One of the Largest U.S. Group Purchasing Organizations
Date:5/12/2008

ssociation and the Annals of Internal Medicine demonstrate, true rapid test turnaround time is critical to reaching maximum results with a fully implemented infection control plan to reduce HAI rates and improve patient care.

About the GeneXpert Molecular Diagnostic Platform

The GeneXpert System is a closed, self-contained, fully-integrated and automated platform that represents a paradigm shift in the automation of molecular analysis, producing accurate results in a timely manner with minimal risk of contamination. The GeneXpert System is the only system to combine on-board sample preparation with real-time PCR (polymerase chain reaction) amplification and detection functions for fully integrated and automated nucleic acid analysis. The system is designed to purify, concentrate, detect and identify targeted nucleic acid sequences thereby delivering answers directly from unprocessed samples. Modular in design, the GeneXpert System has a variety of configurations to meet the broad range of testing demands of any clinical environment.

About Cepheid

Based in Sunnyvale, Calif., Cepheid (Nasdaq: CPHD) is an on-demand molecular diagnostics company that develops, manufactures, and markets fully-integrated systems for genetic analysis in the clinical, industrial and biothreat markets. The company's systems enable rapid, sophisticated genetic testing for organisms and genetic-based diseases by automating otherwise complex manual laboratory procedures. The company's easy-to-use systems integrate a number of complicated and time-intensive steps, including sample preparation, DNA amplification and detection, which enable the analysis of complex biological samples in its proprietary test cartridges. Through its strong molecular bi
'/>"/>

SOURCE Cepheid
Copyright©2008 PR Newswire.
All rights reserved

0

GOOD

Page: 1 2 3 4

Related medicine news :

1. Cepheid Reports Record Revenue of $44.8 Million
2. Cepheid Selected as Vendor of Choice by Connecticut Hospital Association Shared Services Program for Molecular MRSA Surveillance Testing
3. Cepheid Comments on Study Regarding MRSA Surveillance Reported in the Journal of the American Medical Association
4. Cepheid to Present at the Needham Tenth Annual Growth Stock Conference
5. Cepheid and Broadlane Sign Group Purchasing Contract for GeneXpert(R) Systems and Xpert(TM) Molecular Diagnostic Tests, Including Xpert MRSA
6. Cepheid Schedules Teleconference and Webcast for Third Quarter 2007 Results
7. Cepheid to Present at ThinkEquity Partners 5th Annual Growth Conference
8. OxyBand Technologies Signs Army Contract
9. The HealthCentral Network Signs Spunky Midlife Gals for Comedic Relief on Alzheimers, Skin Care Sites
10. Phyhealth Signs Agreement with Argus Dental to Provide Dental Services for Pilot HMO
11. AMDL Signs Letter of Intent to Purchase a China Based Pharmaceutical Distribution Company
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/16/2008)... Declaring that Primary care medicine is in a pre...nt of the American College of Physicians (ACP), to...ers and consumers to issue a call for comprehensiv...nternists and other primary care physicians. , ...care medicine in the U.S., Dr. Dale and other pane...
(Date:5/16/2008)... Fundraiser Seeks to Raise $38 Million for Life-th...ire-USNewswire/ -- Walkers in nearly,every state w...- May 17 and,18 -- by participating in GREAT STRID...c Fibrosis Foundation announced today., May is Na...rosis is a,life-threatening genetic disease that c...
(Date:5/16/2008)...untry needs is more unemployed politicians - and e...stCall/ -- Although nearly all,voters place health...list,a looming federal budgetary crunch means non...current presidential candidates is likely to becom...ty Leader Bill Frist., Jousting with Princeton Un...
(Date:5/16/2008)..., May 16 /PRNewswire-USNewswire/ -- As tropical st...rrawaddy delta, survivors of,Cyclone Nargis are vu...ny,survivors still need assistance, as exposure to... increasingly dire situation., "The people living...cover from this disaster and get back on their fee...
Breaking Medicine News(10 mins):Health News:ACP says major system reforms needed to improve the state of primary care medicine in the US 2Health News:GREAT STRIDES Walks for Cystic Fibrosis Slated for 47 States This Weekend 2Health News:Former Senate Majority Leader, Princeton Economist Joust on Future of Health Care 2Health News:Former Senate Majority Leader, Princeton Economist Joust on Future of Health Care 3Health News:Myanmar Cyclone Survivors Face New Challenges 2
...lowing detection of Alzheimer's disease in a forme...vey calls for further testing of people // who res...oning in 1988. The suggestion has been made in a J... Psychiatry. The death of resident Carole Cross, ...
...ording to an Irish researcher, frequent hiccups to...ng may be an indication of esophageal cancer. // ...e James Connolly Memorial Hospital in Dublin, told...geons in Ireland that 27 percent of patients with ...
...nsplant experts in Britain have accused China of r... them without prior consent of the prisoners and t...ich highlights that organs from executed prisoners...tation purposes in an illegal way, according to re...
...ional Health Service (NHS) which initially funded ...ding the laser treatment to remove the tattoos. //...eds the ?2,500 laser treatment because her tattoos...evless dresses in the summer. Middleton and Heywo...
Other Medicine News:Health News:Call For Testing Of Poisoned Town: Risk Of Alzheimer's Disease 2Health News:Executed Prisoner Organs For Sale In China: BTS Concerned 2
(Date:5/16/2008)... Highlights Include:, -- Results demonstrating th...linically meaningful extension of progression-free...mab to attack both the inside and,outside of the H...ade, -- Data demonstrating activity of TYKERB alo...ple lines of trastuzumab and chemotherapy, LONDON...
(Date:5/16/2008)... MicroRNAs as Potential Biomarkers -- for Lung Ca... in Patients With Cancer of Unknown Primary ...tively Identify Cancer Types With High Sensitivity...sis and Treatment of Cancer Results of microRNA S... Accuracy Exceeding 90% and Specificity of...
(Date:5/16/2008)...Single Molecule with Dual Mechanism May Offer Nove...ure Management, NEW ORLEANS, May 16 /PRNewswire-F...ator in the discovery and development of novel sma...33540, its first-in-class,Dual Acting Receptor Ant...lood pressure reductions in a Phase 2a study in pa...
(Date:5/15/2008)...Trial Results Confirm Efficacy for Population Most...E, Calif., May 16 /-,Bayer ...uticals, Inc.,(Nasdaq: ONXX ) today announced tha...roved overall survival by 47.3 percent (HR=0.68;,p...on with advanced,hepatocellular carcinoma (HCC), o...
Breaking Medicine Technology:GSK Announces Results of First Phase III Trial Evaluating Tykerb(R) (Lapatinib) Plus Herceptin(R) (Trastuzumab) 2GSK Announces Results of First Phase III Trial Evaluating Tykerb(R) (Lapatinib) Plus Herceptin(R) (Trastuzumab) 3GSK Announces Results of First Phase III Trial Evaluating Tykerb(R) (Lapatinib) Plus Herceptin(R) (Trastuzumab) 4GSK Announces Results of First Phase III Trial Evaluating Tykerb(R) (Lapatinib) Plus Herceptin(R) (Trastuzumab) 5GSK Announces Results of First Phase III Trial Evaluating Tykerb(R) (Lapatinib) Plus Herceptin(R) (Trastuzumab) 6GSK Announces Results of First Phase III Trial Evaluating Tykerb(R) (Lapatinib) Plus Herceptin(R) (Trastuzumab) 7Rosetta Genomics to Present Multiple Posters at the 44th Annual Meeting of the American Society of Clinical Oncology (ASCO) 2Rosetta Genomics to Present Multiple Posters at the 44th Annual Meeting of the American Society of Clinical Oncology (ASCO) 3Rosetta Genomics to Present Multiple Posters at the 44th Annual Meeting of the American Society of Clinical Oncology (ASCO) 4Rosetta Genomics to Present Multiple Posters at the 44th Annual Meeting of the American Society of Clinical Oncology (ASCO) 5Rosetta Genomics to Present Multiple Posters at the 44th Annual Meeting of the American Society of Clinical Oncology (ASCO) 6Pharmacopeia's First-in-Class Investigational Therapy PS433540 Achieves Statistically Significant Reductions in Blood Pressure in Hypertensive Patients 2Pharmacopeia's First-in-Class Investigational Therapy PS433540 Achieves Statistically Significant Reductions in Blood Pressure in Hypertensive Patients 3Pharmacopeia's First-in-Class Investigational Therapy PS433540 Achieves Statistically Significant Reductions in Blood Pressure in Hypertensive Patients 4Pharmacopeia's First-in-Class Investigational Therapy PS433540 Achieves Statistically Significant Reductions in Blood Pressure in Hypertensive Patients 5Pharmacopeia's First-in-Class Investigational Therapy PS433540 Achieves Statistically Significant Reductions in Blood Pressure in Hypertensive Patients 6Pharmacopeia's First-in-Class Investigational Therapy PS433540 Achieves Statistically Significant Reductions in Blood Pressure in Hypertensive Patients 7Pharmacopeia's First-in-Class Investigational Therapy PS433540 Achieves Statistically Significant Reductions in Blood Pressure in Hypertensive Patients 8Nexavar Significantly Improves Overall Survival by 47 Percent in Asia-Pacific Liver Cancer Study 2Nexavar Significantly Improves Overall Survival by 47 Percent in Asia-Pacific Liver Cancer Study 3Nexavar Significantly Improves Overall Survival by 47 Percent in Asia-Pacific Liver Cancer Study 4Nexavar Significantly Improves Overall Survival by 47 Percent in Asia-Pacific Liver Cancer Study 5Nexavar Significantly Improves Overall Survival by 47 Percent in Asia-Pacific Liver Cancer Study 6PA Department of Health Warns Consumers About Adverse Reactions From Dietary Supplements 16784 1PA Department of Health Warns Consumers About Adverse Reactions From Dietary Supplements 16784 2CV Therapeutics to Announce 2008 First Quarter Financial Results on Friday April 25 2008 16781 1CV Therapeutics to Announce 2008 First Quarter Financial Results on Friday April 25 2008 16781 2TOFUTTI Announces 2007 Results 16776 1TOFUTTI Announces 2007 Results 16776 2TOFUTTI Announces 2007 Results 16776 3TOFUTTI Announces 2007 Results 16776 4TOFUTTI Announces 2007 Results 16776 5Testosterone Spray Improves Sexual Satisfaction in Women 16771 1Testosterone Spray Improves Sexual Satisfaction in Women 16771 2
... June 4, 2007 – Data presented,today at this...y,(ASCO) meeting in Chicago show that a novel comb...-fluorouracil (5-FU) therapy UFT,(tegafur–ur...response rate in the first-line treatment of metas...dy (Study of CPT-11 with Oxaliplatin combined,with...
...ing a clinically relevant model of,normal human sk...,of abrogating the cytotoxic effect of erlotinib *...m) agent was generally well,tolerated in metastati...similar to conventional vincristine , SOUTH SAN FR...Hana Biosciences (Nasdaq:HNAB), a biopharmaceutica...
Other Medicine Technology:Merck at ASCO 2007: New Data Demonstrate the Value of UFT as an,Important Treatment Option for Patients With Metastatic Colorectal,Cancer 2Merck at ASCO 2007: New Data Demonstrate the Value of UFT as an,Important Treatment Option for Patients With Metastatic Colorectal,Cancer 3Hana Biosciences Presents Data On Two Programs At the American,Society of Clinical Oncology Annual Meeting 2Hana Biosciences Presents Data On Two Programs At the American,Society of Clinical Oncology Annual Meeting 3Hana Biosciences Presents Data On Two Programs At the American,Society of Clinical Oncology Annual Meeting 4Hana Biosciences Presents Data On Two Programs At the American,Society of Clinical Oncology Annual Meeting 5
VascoTip is a unipolar tined permanent pacing lead. Due to advanced technology, VascoTip 9/60 M is compatible to all pacemaker-cavities with the size of IS-1 (3.2 mm), 5 mm, 6 mm.
VascoTip is a unipolar tined permanent pacing lead. Due to advanced technology, VascoTip 9/60 M is compatible to all pacemaker-cavities with the size of IS-1 (3.2 mm), 5 mm, 6 mm.
VascoTip is a unipolar tined permanent pacing lead. Due to advanced technology, VascoTip 9/60 M is compatible to all pacemaker-cavities with the size of IS-1 (3.2 mm), 5 mm, 6 mm.
VascoTip is a unipolar tined permanent pacing lead. Due to advanced technology, VascoTip 9/60 M is compatible to all pacemaker-cavities with the size of IS-1 (3.2 mm), 5 mm, 6 mm.
Medicine Products: